GlassScriptPhysician profile
Dimetris Roubis
NPI 1427074756
$18,159.96
in general payments reported to CMS, 2019-2025
37 companies · $3,936 in 2025
The $3,936 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,163 · 2022: $3,787 · 2023: $4,637 · 2024: $3,638 · 2025: $3,936.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,968.30 |
| Education | $241.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $2,906.61 | 2021-2025 | Nucala, Trelegy Ellipta, Shingrix |
| Regeneron Healthcare Solutions, INC. | $2,576.74 | 2021-2025 | Dupixent |
| Genzyme Corporation | $1,616.75 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $1,592.32 | 2021-2025 | Tezspire, Airsupra, Fasenra |
| Pfizer INC. | $1,105.24 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $1,015.88 | 2021-2025 | |
| Optinose US, INC. | $965.34 | 2021-2025 | |
| Amgen INC. | $946.35 | 2021-2025 | Tezspire, Actimmune |
| Takeda Pharmaceuticals U.S.A., INC. | $915.90 | 2021-2025 | Cuvitru, Eohilia |
| Grifols USA, LLC | $568.90 | 2021-2025 | Xembify |
| Incyte Corporation | $513.13 | 2021-2025 | Opzelura, Opzelura |
| Kaleo, INC. | $446.90 | 2021-2024 | Auvi-Q |
| Abbvie INC. | $375.94 | 2021-2025 | |
| Genentech USA, INC. | $303.88 | 2021-2025 | Xolair |
| Teva Pharmaceuticals USA, INC. | $301.93 | 2021-2022 |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Csl Behring | $232.71 | 2023-2025 | Hizentra |
| Ars Pharmaceuticals Operations, INC. | $231.43 | 2025 | Neffy |
| Octapharma USA, INC. | $217.13 | 2021-2024 | Cutaquig |
| Mylan Specialty L.P. | $185.81 | 2021-2024 | Yupelri |
| Bio Products Laboratory USA, INC. | $140.03 | 2021-2023 | Coagadex, Gammaplex |
| Aimmune Therapeutics, INC. | $107.87 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $105.83 | 2021-2023 | Spiriva Respimat, Stiolto Respimat |
| Blueprint Medicines Corporation | $98.91 | 2023-2024 | Ayvakit |
| Sanofi-Aventis U.S. LLC | $98.00 | 2023 | |
| Lilly USA, LLC | $89.32 | 2024-2025 | Ebglyss |
| Covis Pharma Gmbh | $86.74 | 2021 | |
| Hikma Pharmaceuticals USA | $80.76 | 2021-2023 | Ryaltris |
| Phadia US INC. | $76.87 | 2021-2024 | Immunocap |
| Verona Pharma, INC. | $62.18 | 2025 | Ohtuvayre |
| Eyevance Pharmaceuticals LLC | $40.33 | 2021 | |
| Leo Pharma INC. | $37.92 | 2024-2025 | Adbry, Anzupgo |
| Gc Biopharma USA, INC. | $23.07 | 2024 | Alyglo |
| Biocryst US Sales Co., LLC | $22.79 | 2024 | Orladeyo |
| Adma Biomanufacturing LLC | $17.76 | 2021 | |
| Circassia INC. | $17.70 | 2021 | |
| Merck Sharp & Dohme LLC | $17.57 | 2021 | |
| Aytu Biopharma, INC. | $17.42 | 2023 | Karbinal |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dimetris Roubis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.